ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Telesis Bio Inc

Telesis Bio Inc (TBIO)

0.3184
-0.003
(-0.93%)
Closed April 26 4:00PM
0.3184
0.00
( 0.00% )
Pre Market: 4:00AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.3184
Bid
0.276
Ask
0.39
Volume
-
0.00 Day's Range 0.00
0.2997 52 Week Range 3.01
Market Cap
Previous Close
0.3184
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
787,873
Shares Outstanding
29,983,709
Dividend Yield
-
PE Ratio
-0.20
Earnings Per Share (EPS)
-1.64
Revenue
27.51M
Net Profit
-49.02M

About Telesis Bio Inc

Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of... Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of virtually error-free DNA and mRNA at a useable scale. Its on-market and planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp DBC, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, BioXp DBC kits, Benchtop reagents and Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS). BioXp 3250 system is a push-button, walkaway, end-to-end automated workstation that offers endpoint-ready synthetic DNA in as few as 8 hours and mRNA in less than 24 hours. BioXp DBC is engaged in delivering on-demand enzymatic DNA synthesis with design-to-endpoint-ready synthetic RNA in as few as 24 hours. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Headquarters
Wilmington, Delaware, USA
Founded
1970
Telesis Bio Inc is listed in the Lab Analytical Instruments sector of the NASDAQ with ticker TBIO. The last closing price for Telesis Bio was $0.32. Over the last year, Telesis Bio shares have traded in a share price range of $ 0.2997 to $ 3.01.

Telesis Bio currently has 29,983,709 shares outstanding. The market capitalization of Telesis Bio is $9.59 million. Telesis Bio has a price to earnings ratio (PE ratio) of -0.20.

TBIO Latest News

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the...

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01876.239572906240.29970.350.2997771430.32078247CS
4-0.1116-25.95348837210.430.47850.2997619720.35686277CS
12-0.0265-7.683386488840.34490.8590.29977878730.61670538CS
26-0.4616-59.17948717950.780.8590.29975100030.5555257CS
52-2.2716-87.70656370662.593.010.29972800240.652787CS
156-22.8316-98.624622030223.1537.9850.299765464823.64649546CS
260-9.6716-96.81281281289.9937.9850.299774147720.0081743CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INHDInno Holdings Inc
$ 0.88
(39.57%)
1.37M
YYAIConnexa Sports Technologies Inc
$ 0.9299
(28.94%)
560
CTCXCarmell Corporation
$ 2.55
(22.01%)
211
INDPIndaptus Therapeutics Inc
$ 2.50
(18.48%)
48
FLJFLJ Group Limited
$ 0.6316
(14.84%)
152.85k
CLVRClever Leaves Holdings Inc
$ 1.94
(-52.80%)
12.65k
ADXNAddex Therapeutics Ltd
$ 7.94
(-50.68%)
1.55k
ISUNiSun Inc
$ 0.1415
(-15.77%)
90.37k
NWGLNature Wood Group Ltd
$ 4.33
(-14.17%)
12.88k
CYCCCyclacel Pharmaceuticals Inc
$ 1.30
(-13.91%)
2.54k
PEGYPineapple Energy Inc
$ 0.0695
(11.02%)
2.07M
INHDInno Holdings Inc
$ 0.88
(39.57%)
1.37M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0438
(-6.81%)
883.27k
AKANAkanda Corporation
$ 0.1178
(14.37%)
738.56k
TSLATesla Inc
$ 178.60
(6.13%)
686.49k

TBIO Discussion

View Posts
TOM611 TOM611 2 months ago
Go. TBiO. Life. Enhancing. Patent
πŸ‘οΈ0
Hikiro Hikiro 2 months ago
I personally see this consolidating Monday between .55 and .45
πŸ‘οΈ0
glenn1919 glenn1919 2 months ago
TBIO...............................................https://stockcharts.com/h-sc/ui?s=TBIO&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
XenaLives XenaLives 2 months ago
This one scares the crap out of me...

Imagine replication of COVID ( or the next worst thing) with out a biological matrix.

December 5, 2023 | LIVE WEBINAR
Unlocking the Potential of mRNA as a Tool for Immuno-Oncology Therapy Discovery and Development
Immuno-oncology is a rapidly growing area for therapeutic development. With the adoption of various autologous cell therapies and an increased focus on more broadly applicable allogeneic treatments and multi-specific therapies, the complexity of these development activities is also increasing. With this drive to increased complexity and the inherent risks associated with potential failure in Phase 1 clinical trials, it is critical to have a solid scientific foundation for the development of these next-generation immunotherapies. This talk will focus on how to overcome the limitations associated with traditional viral vector based recombinant TCR gene expression to build hundreds of candidates a week, resulting in improved confidence in screening and lead optimization. With the direct use of mRNA to drive transient modulation of cellular phenotypes, potential candidates can be screened quickly and cost-effectively. Come and learn how immuno-oncology researchers are automating synthetic biolological...



$TBIO Granted EUR Patent #3503915 For "GENETICALLY ENGINEERED VIBRIO NATRIEGENS (HOST ORGANISM FOR CLONING AND MANIPULATING DNA)".https://t.co/9dekeJkgGu pic.twitter.com/Mj3hMaJPML— Patent_Stocks (@US_Patent_Plays) February 22, 2024
πŸ‘οΈ0
TOM611 TOM611 2 months ago
Wow, a patent to clone that’s incredible
πŸ‘οΈ0
observer21 observer21 2 months ago
Gosh. Such wisdom. Thanks for enlightening us with that critical information.
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 months ago
dilutive bio stocks under 1.00 are like pink sheets on steroids...ya better know how to trade em or you will lose yo money fast!!!
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 months ago
TBIO: Right here in my San Diego --- grab some?????
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 months ago
Chart plays are never tricky. Stick to bullish stocks. Day trading pop and drops, ya better have skills and understand intraday 60 min charting, order flow and how to spot the shorts.
πŸ‘οΈ0
TimeFades TimeFades 2 months ago
Tricky day
πŸ‘οΈ0
Awl416 Awl416 2 months ago
New highs AH
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 months ago
LETS JUST SAY MOST AH POPS ARE DILUTION, ESPECIALLY THE BIO SPACE.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
THX
πŸ‘οΈ0
TimeFades TimeFades 2 months ago
Another short opp
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 2 months ago
AFTER HOUR DILUTION TAKING PLACE...CHASE AND CRY PLAY!
πŸ‘οΈ0
Awl416 Awl416 2 months ago
What leaked?
πŸ‘οΈ0
Zorro Zorro 2 months ago
Nice one!
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 months ago
TBIO: VIBRIO NATRIEGENS (So, what's NEW, Pussycat??!!)

πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
$TBIO Granted EUR Patent #3503915 For "GENETICALLY ENGINEERED VIBRIO NATRIEGENS (HOST ORGANISM FOR CLONING AND MANIPULATING DNA)".https://t.co/9dekeJkgGu pic.twitter.com/Mj3hMaJPML— Patent_Stocks (@US_Patent_Plays) February 22, 2024
πŸ‘οΈ0
observer21 observer21 3 months ago
Anyone know why the huge jump in price and volume?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock